CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 173 enrolled
Drug / intervention
positron emission tomography +2 moreprocedure
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Histologically confirmed prostate adenocarcinoma
  • ✓At least 50% sustained increase in PSA, documented over minimum 3 observations at least 1 week apart
  • ✓Development of new lesions on bone scintigraphy or >50% increase in measurable disease on CT/MRI
  • ✓Metastatic disease
Key exclusion· 3
  • ✕Clinically significant cardiac disease
  • ✕Clinically significant pulmonary disease
  • ✕Active infection not controlled by antibiotics

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002981
NCT00002981N/ACompleted
CompareCT.gov

11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 27, 2003·Updated Jun 3, 2024

In Brief

A clinical study evaluating positron emission tomography, fludeoxyglucose F 18, and 1 other intervention for Prostate Cancer. Completed, enrolled 173 participants across 1 site.

Detailed Summary

RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJan 1, 1997
Primary CompletionJun 12, 2023
TodayJul 2, 2026
Enrollment to primary: 26.4 yearsPosted 23.4 years ago

Interventions

positron emission tomographyprocedure

fludeoxyglucose F 18radiation

methionine C 11radiation